In a letter to the company, Drug controller Dr VG Somani said that a Member of Parliament (MP) has informed that the cost of treatment from FabiFlu (Favipiravir) will come to around Rs 12,500, which is not good for the poor as well as the middle-class families.

The company has received approval to market Butalbital, Acetaminophen and Caffeine medicines in the strengths of 50 mg/325 mg/40 mg. This combination of medicines is used in the treatment of patients suffering from symptoms of tension headaches.

Since the last 31 trading sessions, the stock is trading in contracting consolidation, which resulted in the formation of a symmetrical triangle pattern. As of now, the momentum in prices has been narrowed substantially and its prices have reached near an apex point of the triangle, which suggests that the stock is likely to give a breakout in the coming days.

Due to a narrow range, Bollinger Bands have contracted, which indicates an early signal of a bigger move. Also, on the lower timeframe, i.e. 60 minutes, the stock is on the verge of giving a breakout of downward sloping trendline.

Sensex and Nifty reclaimed their important psychological level of 37,000 and 10,900 with a strong close on Friday. Post a solid close, market participants would expect the move to continue. However, the early trends in SGX Nifty suggests that bulls are likely to face Monday morning blues. Further, cues from Asian peers too are negative.

The sign of exhaustion would be confirmed only if the index manages to close below 10,562 levels. On the upside, the level of 11,000-11,280 is likely to act as a resistance zone. Stocks in news: M&M Financial Services, Glenmark Pharmaceuticals, Cadila Healthcare, Vodafone Idea, NLC India, Selan Exploration.

The net profit margin in Q1FY21 came in at 1.43 per cent , which declined by 7.90 per cent  YoY. The net profit margin in Q1FY20 was at 9.33 per cent.

Provisions and contingencies stood at Rs 3,891.52 crore in Q1FY21, which increased by 48.9 per cent YoY, as against Rs 2,613.66 crore in Q1FY20.

New Fund Offers (NFOs) that are open for subscription.

Gross Direct Premium Income (GDPI) of the company stood at Rs 3,302 crore in Q1FY21 which declined by 5.3 per cent YoY compared to Rs 3,487 crore in Q1FY20.